Education
About Us
Working with TipRanks
Follow Us
Protagenic Therapeutics (PTIX)
NASDAQ:PTIX
Total Valuation
Protagenic Therapeutics has a market cap or net worth of $2.38M. The enterprise value is $5.34M.
Market Cap$2.38M
Enterprise Value$5.34M
Share Statistics
Protagenic Therapeutics has 1,927,898 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,927,898
Owned by Insiders―
Owned by Institutions3.36%
Financial Efficiency
Protagenic Therapeutics’s return on equity (ROE) is -5.45 and return on invested capital (ROIC) is -562.70%.
Return on Equity (ROE)-5.45
Return on Assets (ROA)-2.82
Return on Invested Capital (ROIC)-562.70%
Return on Capital Employed (ROCE)-5.63
Revenue Per Employee0.00
Profits Per Employee-5.53M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagenic Therapeutics is ―. Protagenic Therapeutics’s PEG ratio is 3.50.
PE Ratio―
PS Ratio0.00
PB Ratio33.18
Price to Fair Value33.18
Price to FCF-7.97
Price to Operating Cash Flow-0.87
PEG Ratio3.50
Income Statement
In the last 12 months, Protagenic Therapeutics had revenue of 0.00 and earned -5.53M in profits. Earnings per share was -1.13.
Revenue0.00
Gross Profit-50.29K
Operating Income-5.70M
Pretax Income-5.53M
Net Income-5.53M
EBITDA-5.47M
Earnings Per Share (EPS)-1.13
Cash Flow
In the last 12 months, operating cash flow was -12.09M and capital expenditures 0.00, giving a free cash flow of -12.09M billion.
Operating Cash Flow-12.09M
Free Cash Flow-12.09M
Free Cash Flow per Share-6.27
Dividends & Yields
Protagenic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-2.02
52-Week Price Change-83.36%
50-Day Moving Average2.15
200-Day Moving Average3.24
Relative Strength Index (RSI)25.86
Average Volume (3m)102.28K
Important Dates
Protagenic Therapeutics upcoming earnings date is Apr 1, 2024, Before Open (Confirmed).
Last Earnings DateNov 16, 2021
Next Earnings DateApr 1, 2024
Ex-Dividend Date―
Financial Position
Protagenic Therapeutics as a current ratio of 2.00, with Debt / Equity ratio of -41.75%
Current Ratio2.00
Quick Ratio2.00
Debt to Market Cap0.00
Net Debt to EBITDA0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagenic Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Protagenic Therapeutics EV to EBITDA ratio is -5.80, with an EV/FCF ratio of -7.54.
EV to Sales0.00
EV to EBITDA-5.80
EV to Free Cash Flow-7.54
EV to Operating Cash Flow-7.54
Balance Sheet
Protagenic Therapeutics has $2.72M in cash and marketable securities with $3.16M in debt, giving a net cash position of -$433.60K billion.
Cash & Marketable Securities$2.72M
Total Debt$3.16M
Net Cash-$433.60K
Net Cash Per Share-$0.22
Tangible Book Value Per Share$0.21
Margins
Gross margin is 300.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin300.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Protagenic Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast64.85%